Viral Aquaculture Disease Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global viral aquaculture disease treatment market size is likely to be valued at US$1.6 billion in 2026 and is estimated to reach US$2.8 billion by 2033, growing at a CAGR of 8.3% during the forecast period from 2026 to 2033, driven by rising disease losses in intensive farming and wider use of vaccines. Oral and RNA-based products are also widening treatment options.

Driver - Rising Disease Pressure in Intensive Farming to Lift Treatment Demand

Aquaculture is now a core food source, and disease threatens its growth. The Food and Agriculture Organization (FAO) reported record global aquaculture production of 130.9 million tons in 2022. Aquaculture of aquatic animals reached 94.4 million tons, or 51% of total aquatic animal production. Asia accounted for 70% of aquatic animal production. Dense stocking and rapid trade raise the risk that viruses spread. Higher output means each outbreak now costs more. Producers are therefore moving from reactive care to planned prevention.

Viral losses are clear in Norwegian salmon data. The Fish Health Report 2025 recorded 54.8 million dead salmon at sea, with an annual sea-phase mortality risk of 14.2%. ISA was confirmed at 18 sea sites, and pancreatic disease (PD) was detected in 44 cases. Not all deaths are viral, but the figures show why producers invest in prevention.

Established Vaccination Programs to Bolster Market Growth

Vaccination is the most proven tool in finfish. The Norwegian report says about 190 million doses of vaccines containing ISA virus were sold in 2025, at the same level as 2024. Nearly all salmon moved to sea in 2025 received a new vaccine that includes M. viscosa, a bacterial pathogen. This shows how multi-disease vaccine programs are now routine.

Product ownership is also consolidating. On July 9, 2024, Merck Animal Health completed its acquisition of Elanco's aqua business. The deal included CLYNAV, a DNA-based vaccine that protects Atlantic salmon against PD. Larger animal health groups can fund field trials and global distribution. That supports faster rollout of new vaccines.

Restraint - Few Licensed Options for Key Viruses May Limit Growth

Many viral diseases still have no licensed vaccine or antiviral. A 2025 review of aquatic RNA viruses lists none for viral hemorrhagic septicemia virus (VHSV), spring viremia of carp virus, tilapia lake virus (TiLV), yellow head virus, Taura syndrome virus, or infectious myonecrosis virus. Mortality can be severe. TiLV can reach up to 90%, and infectious hematopoietic necrosis virus (IHNV) can reach 100% in early life stages. Infectious myonecrosis virus losses exceeded US$1 billion in 2011.

Efficacy gaps add to the challenge. The same review says commercial ISA vaccines have shown insufficient efficacy. Seven ISA outbreaks were confirmed in 2025 at sites with vaccinated fish. Injection is also hard for small shrimp and juvenile fish. As of a U.S. Department of Agriculture grant report, no commercial therapeutics existed for white spot disease. Farmers in lower-cost regions may therefore rely on biosecurity alone.

Opportunity - Oral RNA-based Products to Open Shrimp and Warm-water Markets

Shrimp lack a classic adaptive immune system, so standard vaccines have limits. Researchers are testing RNA interference (RNAi) for white spot syndrome virus (WSSV). A 2012-13 U.S. trial with RNA-expressing algae and yeast showed no effective protection, which shows the technical risk. WSSV can cause 80% to 100% mortality in ponds within 7 to 10 days, according to that report.

Newer work targets delivery. A University of Arizona project, funded by a US$350,000 grant from the U.S. Department of Agriculture (USDA), ran from 2022 to 2024. It tested a shrimp viral vector to deliver hairpin RNA against WSSV through feed. In September 2023, ViAqua Therapeutics raised US$8.25 million for an oral shrimp vaccine. Its first product is an RNA-particle feed supplement, which trade press says was launched with Skretting.

Fast-growing Asian Shrimp and Tilapia Farming to Widen Addressable Demand

Asia holds the largest base of unmet disease demand. India exports about 0.71 million tons of farmed shrimp worth US$5.48 billion, or about 25% of global shrimp trade, according to a 2025 Frontiers study. The study estimated shrimp disease losses at US$728.55 million in 2021-22. EHP, a non-viral microsporidian, caused 78.41% of that loss. WSSV caused US$90.25 million, and its frequency fell from 25% to 6.48%.

Tilapia adds to the opportunity. The 2025 review says TiLV, first identified in 2014, has been reported in 17 countries. Global tilapia output was nearly 7 million tons in 2024, with a market of about US$9 billion. No licensed TiLV vaccine is listed, so first movers can gain share. Producers in Asia will likely value low-cost oral and immersion products.

Treatment Type Insights

Vaccines are predicted to lead with a share of about 52.4% in 2026, as immunization is routine in salmonid farming. The Norwegian report shows about 190 million ISA-virus vaccine doses sold in 2025. Commercial vaccines also exist for PD and infectious pancreatic necrosis in salmon. Repeat purchases at every smolt batch keep demand steady.

Antivirals and RNAi therapeutics are estimated to be the fastest-growing treatment type over the forecast period, as developers target viruses with no vaccine. Oral RNA products for WSSV are the early focus. Developers see value in tools that act fast once an outbreak starts. Evidence is still limited, and several trials have failed. Field data and regulatory clearance will decide how fast this segment scales.

Species Insights

Finfish is anticipated to dominate with a share of around 61.5% in 2026, as salmon and trout are vaccinated at scale. Scotland's salmon output reached 192,000 tons in 2024, up 27% from 150,949 tons in 2023. Larger harvests raise the value at risk from each outbreak. Germany reported 82 IHNV and 15 VHSV cases in trout in 2021.

Crustaceans are expected to be the fastest-growing species segment over the forecast period, as shrimp farming expands and WSSV remains a major threat. Shrimp accounts for most of the unmet need, since DNA viruses cause about 99% of crustacean outbreaks. Oral and in-feed products suit this segment best, as injection is not practical.

Europe Viral Aquaculture Disease Treatment Market Trends

Europe is predicted to dominate in 2026 globally with a share of approximately 35.8%, due to an established salmon-farming industry, extensive aquatic animal health monitoring, and widespread use of preventive vaccination in commercial fish production. Norway, the U.K., and other European aquaculture producers place considerable emphasis on early disease detection, mortality monitoring, biosecurity, and coordinated responses to infectious outbreaks. These practices support demand for vaccines, diagnostic services, veterinary health products, and disease-management technologies.

Germany Viral Aquaculture Disease Treatment Market Trends

A share of nearly 12.6% is expected to be held by Germany in 2026 in Europe, supported by its freshwater aquaculture sector, particularly trout and carp farming. Infectious haematopoietic necrosis virus (IHNV) and viral haemorrhagic septicaemia virus (VHSV) are important health concerns for susceptible farmed fish, making surveillance, farm-level biosecurity, and rapid laboratory diagnosis essential components of disease management. Outbreaks can cause substantial mortality, especially among younger fish, while movement of infected fish and contaminated equipment can contribute to disease transmission.

U.K. Viral Aquaculture Disease Treatment Market Trends

The U.K. is likely to hold a share of about 15.7% in Europe in 2026, with Scottish salmon farming representing a major source of demand. Commercial salmon producers require comprehensive fish-health programs to manage viral diseases, maintain stock survival, and limit financial losses associated with mortality and production interruptions. Vaccination, health monitoring, coordinated veterinary support, and farm biosecurity are therefore important components of production management.

Asia Pacific Viral Aquaculture Disease Treatment Market Trends

Asia Pacific is anticipated to be the fastest-growing region, driven by its extensive aquaculture industry, high-volume shrimp production, and large-scale farming of tilapia and carp create substantial demand for solutions that prevent and manage viral infections. White spot syndrome virus (WSSV) remains a major concern for shrimp producers, while tilapia lake virus (TiLV) threatens tilapia farming in several Asian countries. These diseases can cause rapid mortality, disrupt production cycles, and affect farmers' export earnings.

China Viral Aquaculture Disease Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 39.4%. Its extensive production of carp, tilapia, and other farmed aquatic species creates a substantial requirement for disease surveillance and preventive health management. Viral diseases can affect production at multiple stages, from hatcheries and nurseries to grow-out farms, making early detection and containment important for reducing economic losses. Producers and research institutions are therefore important potential users of diagnostic assays, fish vaccines, pathogen-monitoring systems, and emerging antiviral technologies.

India Viral Aquaculture Disease Treatment Market Trends

In 2026, India is projected to account for a share of just about 17.8% in Asia Pacific, with shrimp aquaculture and seafood exports representing important sources of demand. White spot syndrome virus remains a significant threat to farmed shrimp as infections can cause severe mortality and undermine production yields. Although hepatopancreatic microsporidiosis caused by Enterocytozoon hepatopenaei (EHP) is a major shrimp-health concern, it is a parasitic microsporidian infection rather than a viral disease and should be distinguished from WSSV when assessing this market.

North America Viral Aquaculture Disease Treatment Market Trends

North America is expected to hold a share of roughly 17.6% in 2026 globally, owing to established aquatic animal health research, commercial salmon farming in Canada, and research programs investigating emerging approaches to shrimp and finfish disease control. Vaccines and preventive health products are particularly relevant to salmon production, where viral infections can result in substantial economic losses. Canada's licensed DNA vaccine against infectious haematopoietic necrosis virus (IHNV), marketed as Apex-IHN, illustrates the role of biotechnology in commercial aquaculture disease prevention.

U.S. Viral Aquaculture Disease Treatment Market Trends

A share of nearly 71.5% is predicted to be held by the U.S. in 2026 in North America, supported by its research infrastructure, aquatic animal health expertise, and investments in biotechnology. Federal research funding and university-led programs contribute to the development of alternative approaches for controlling viral infections that lack effective commercial treatments. White spot syndrome virus is an important example as no established curative treatment is available for infected shrimp, creating interest in RNAi, gene-silencing technologies, and improved pathogen-detection methods.

The global viral aquaculture disease treatment market is moderately consolidated, with large animal health groups alongside specialized biotech firms. Merck Animal Health holds CLYNAV, a DNA vaccine for PD in Atlantic salmon, through its purchase of Elanco's aqua business. Virbac and Pebble Labs signed a 2020 agreement to develop WSSV prevention. ViAqua Therapeutics is developing oral shrimp products.

Competition is shifting toward oral delivery, multi-disease vaccines, and shrimp solutions. Companies are adding RNA platforms and local partners to reach Asian farms. Evidence will decide winners, as many products remain experimental. Players with field data, distribution reach, and low-cost formats are better placed to grow.

Key Industry Developments:

• In July 2026, researchers reported the development of DNA vaccines encoding the VP26 protein of white spot syndrome virus (WSSV), with one formulation incorporating flagellin as an immune-stimulating adjuvant. Published in Aquaculture Reports, the study found 58–67% relative percent survival in vaccinated Pacific white shrimp seven days after vaccination, compared with complete mortality in the unvaccinated control group following a lethal viral challenge.
• In April 2026, researchers published a study in Scientific Reports evaluating a formalin-inactivated, cell-culture-derived vaccine against tilapia lake virus (TiLV) in Nile tilapia. The vaccine achieved 100% relative percent survival when administered by injection and 83.88% when administered by immersion following viral challenge.
• In June 2025, researchers published a study in the Journal of Fish Diseases evaluating a chitosan nanoparticle-based recombinant vaccine targeting segment 4 of TiLV. Developed by researchers from Thai academic and research institutions, the vaccine was designed for immersion administration, potentially reducing the handling requirements associated with individual fish injections. The formulation achieved a relative percent survival of 25% in laboratory challenge tests and 31.88% under field conditions compared with unvaccinated groups.